Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer.

ABSTRACT:

Introduction

Immunotherapy has become a key treatment for patients with advanced non-small-cell lung cancer (NSCLC). While a survival advantage has been proven for patients who are medically fit, it is unknown whether a benefit exists for patients with poor performance status (PS).

Patients and methods

We performed a retrospective analysis of NSCLC patients who received immunotherapy in our health system. Age and PS at the time of initial immunotherapy administration were assigned based on physician documentation. Radiographic response and date of progression were assigned according to the treating physician's assessment and confirmed by the study team. Immune-related adverse events were extracted from records.

Results

We identified 285 NSCLC patients who received imm

SUBMITTER: Ahmed T 

PROVIDER: S-EPMC7305948 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature